Objective To investigate the effectiveness of self-prescribed Changning Formula combined with Mesalazine in the treatment of ulcerative colitis(UC),and to analyze its effect on protein kinase R-like endoplasmic reticulum kinase(PERK)/nuclear factor κB(NF-κB)pathway.Methods A total of 100 patients with UC admitted to our hospital from January 2021 to January 2024 were selected and divided into control group and combined group by random number table method,with 50 cases in each group.The control group was given Mesalazine,and the combined group was given self-prescribed Changning Formula combined with Mesalazine.After 2 months of treatment,the effectivenesses in two groups were compared.The clinical symp-toms,disease activity(Mayo index score),colonoscopy pathological status(Baron score),mucosal healing status(Geboes index)and PERK/NF-κB pathway-related protein levels in peripheral blood mononuclear cells[phosphorylated PERK(P-PERK),phos-phorylated eukaryotic initiation factor 2α(P-eIF2α),phosphorylated NF-κB(P-NF-κB)],the levels of PERK/NF-κB pathway downstream factors[interleukin-1β(IL-1β),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),interleukin-8(IL-8)]before and after treatment,as well as adverse reactions were compared between the two groups.Results The total effective rate of the combined group was 96.00％,which was higher than that of the control group(76.00％),and the clinical symptom score was lower than that of the control group(both P＜0.05).After treatment,the Mayo index score,Baron score,and Geboes index score in the combined group were(2.32±0.28),(0.51±0.11),and(0.41±0.10),respectively,which were lower than those in the control group[(3.45±0.50),(1.17±0.28),and(1.00±0.22),all P＜0.05].After treatment,the levels of P-PERK,P-eIF2α,and P-NF-κB in peripheral blood mononuclear cells in the combined group were(1.07±0.14),(0.88±0.14),and(0.95±0.18),respectively,which were lower than those in the control group[1.85±0.20),(1.29±0.23),and(1.14±0.23),all P＜0.05].The levels of serum IL-1 β,TNF-α,IL-6,and IL-8 in the combined group after treatment were(4.02±1.26)pg/mL,(6.15±1.64)pg/mL,(8.52±2.04)pg/mL,and(25.34±5.28)pg/mL,respectively,which were lower than those in the control group[(6.00±1.54)pg/mL,(8.79±2.33)pg/mL,(11.23±3.19)pg/mL,and(41.78±9.34)pg/mL,all P＜0.05].The inci-dence of adverse reactions in the combined group was 4.00％,and the difference was not significant compared to the control group(8.00％,P＞0.05).Conclusion The effectiveness and safety of self-prescribed Changning Formula combined with Me-salazine in the treatment of UC are confirmed.It can improve clinical symptoms,control disease progression and alleviate inflam-matory response,the mechanism of which may be related to inhibition PERK/NF-κB pathway activation.

Objective To investigate the effectiveness of self-prescribed Changning Formula combined with Mesalazine in the treatment of ulcerative colitis(UC),and to analyze its effect on protein kinase R-like endoplasmic reticulum kinase(PERK)/nuclear factor κB(NF-κB)pathway.Methods A total of 100 patients with UC admitted to our hospital from January 2021 to January 2024 were selected and divided into control group and combined group by random number table method,with 50 cases in each group.The control group was given Mesalazine,and the combined group was given self-prescribed Changning Formula combined with Mesalazine.After 2 months of treatment,the effectivenesses in two groups were compared.The clinical symp-toms,disease activity(Mayo index score),colonoscopy pathological status(Baron score),mucosal healing status(Geboes index)and PERK/NF-κB pathway-related protein levels in peripheral blood mononuclear cells[phosphorylated PERK(P-PERK),phos-phorylated eukaryotic initiation factor 2α(P-eIF2α),phosphorylated NF-κB(P-NF-κB)],the levels of PERK/NF-κB pathway downstream factors[interleukin-1β(IL-1β),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),interleukin-8(IL-8)]before and after treatment,as well as adverse reactions were compared between the two groups.Results The total effective rate of the combined group was 96.00％,which was higher than that of the control group(76.00％),and the clinical symptom score was lower than that of the control group(both P＜0.05).After treatment,the Mayo index score,Baron score,and Geboes index score in the combined group were(2.32±0.28),(0.51±0.11),and(0.41±0.10),respectively,which were lower than those in the control group[(3.45±0.50),(1.17±0.28),and(1.00±0.22),all P＜0.05].After treatment,the levels of P-PERK,P-eIF2α,and P-NF-κB in peripheral blood mononuclear cells in the combined group were(1.07±0.14),(0.88±0.14),and(0.95±0.18),respectively,which were lower than those in the control group[1.85±0.20),(1.29±0.23),and(1.14±0.23),all P＜0.05].The levels of serum IL-1 β,TNF-α,IL-6,and IL-8 in the combined group after treatment were(4.02±1.26)pg/mL,(6.15±1.64)pg/mL,(8.52±2.04)pg/mL,and(25.34±5.28)pg/mL,respectively,which were lower than those in the control group[(6.00±1.54)pg/mL,(8.79±2.33)pg/mL,(11.23±3.19)pg/mL,and(41.78±9.34)pg/mL,all P＜0.05].The inci-dence of adverse reactions in the combined group was 4.00％,and the difference was not significant compared to the control group(8.00％,P＞0.05).Conclusion The effectiveness and safety of self-prescribed Changning Formula combined with Me-salazine in the treatment of UC are confirmed.It can improve clinical symptoms,control disease progression and alleviate inflam-matory response,the mechanism of which may be related to inhibition PERK/NF-κB pathway activation.